Evaluation of Efficacy and Safety of Epalrestat (150 mg) Compared to Epalrestat (50 mg) in Patients Suffering from Diabetic Peripheral Neuropathy

Evaluation of Efficacy and Safety of Epalrestat (150 mg) Compared to Epalrestat (50 mg) in Patients Suffering from Diabetic Peripheral Neuropathy

Introduction: Epalrestat is currently the only Aldose Reductase Inhibitor (ARI) approved to treat symptoms of Diabetic Peripheral Neuropathy (DPN). The efficacy and safety of Epalrestat 50 mg TDS have been established in clinical practice, however compliance is challenging. Aim: To evaluate efficacy...

Full description

Bibliographic Details
Main Authors: Sachin Devendrarao Shende, Mirza Shiraz Baig, Sudhakar Madhukar Doifode
Format: Article
Language:English
Published: JCDR Research and Publications Private Limited 2018-04-01
Series:Journal of Clinical and Diagnostic Research
Subjects:
aldose reductase inhibitor
diabetes mellitus
hyperglycaemia
Online Access:https://jcdr.net/articles/PDF/11444/32716_CE(RA1)_F(AP)_PF1(MJ_AP)_PFA(MJ_AP)_PB(MJ_AP)_PN(AP)_PFA2(MJ_AP).pdf

Internet

https://jcdr.net/articles/PDF/11444/32716_CE(RA1)_F(AP)_PF1(MJ_AP)_PFA(MJ_AP)_PB(MJ_AP)_PN(AP)_PFA2(MJ_AP).pdf

Similar Items